# CellCentric

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cellcentric

- Industry: Biotechnology
- Headquarters: Cambridge, UK
- Website: www.cellcentric.com
- Total disclosed funding: $567M
- Investors on record: 17

## About

CellCentric Ltd, based in the UK, is focused on developing innovative pharmaceutical therapies, particularly targeting cancer treatment through advanced molecular inhibitors. Founded in 2003 and headquartered in Cambridge, UK, CellCentric Ltd concentrates on the development of pharmaceutical therapies, specifically their lead product, inobrodib. The company was co-founded by Azim Surani, with Will West serving as CEO. In May 2026, CellCentric Limited raised USD 220 million in series D funding led by Venrock, with participation from Fidelity Investments, HBM Partners, Sofinnova Partners, Avego, BrightEdge Ventures, Forbion, Pfizer Inc., and RA Capital Management.

CellCentric specializes in innovative pharmaceutical therapies, with its core product, inobrodib, a first-in-class small molecule inhibitor. This drug selectively targets the p300/CBP proteins to disrupt cancer cell growth, particularly in treating multiple myeloma. Inobrodib is undergoing clinical trials and is designed for oral administration, aiming to ease the treatment process for patients. Their clientele consists mainly of healthcare providers and oncology specialists across North America, Europe, and parts of Asia, who are seeking new cancer therapy options. CellCentric's revenue model involves partnerships with research institutions and pharmaceutical companies for the development and commercialization of inobrodib. The revenue anticipated from licensing agreements and future sales hinges on the regulatory approval and market entry of inobrodib.

The company will use the May 2026 funding to support registration trials, continue development of its drug candidate, and advance studies across multiple treatment settings.

## Funding rounds

- Round, Nov 3, 2026, $220M — Venrock Healthcare Capital Partners, Forbion, HBM Healthcare, Fidelity Management & Research Company, RA Capital Management, Sofinnova Partners, Pfizer
- Series D, May 1, 2026, $220M — Sofinnova Partners, HBM Partners, Venrock, Forbion, Fidelity Investments, Pfizer Inc., RA Capital Management, Avego, BrightEdge Ventures
- Series C, May 9, 2025, $120M — Forbion, RA Capital Management, Avego, BrightEdge Ventures
- Series B, Mar 11, 2011, $5.5M — 5Y Capital, Takeda Ventures
- Series A, May 21, 2004, $1.1M — Avlar BioVentures, Providence Investment Company

## Investors

- Avlar BioVentures (https://capitalatlas.ai/funds/avlar-bioventures) — Series A
- Providence Investment Company — Series A
- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Series B
- Takeda Ventures (https://capitalatlas.ai/funds/takeda-ventures) — Series B
- Forbion (https://capitalatlas.ai/funds/forbion) — Series C, Series D
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series C, Series D
- Avego (https://capitalatlas.ai/funds/avego) — Series C, Series D
- BrightEdge Ventures (https://capitalatlas.ai/funds/brightedge-ventures) — Series C, Series D
- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Series D
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series D
- Venrock (https://capitalatlas.ai/funds/venrock) — Series D
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series D
- Pfizer Inc. — Series D
- Venrock Healthcare Capital Partners (https://capitalatlas.ai/funds/venrock-healthcare-capital-partners)
- HBM Healthcare
- Fidelity Management & Research Company
- Pfizer